LEGENDS OF SUPPLEMENTARY FIGURES

Suppl Figure 1. (A) Expression of cytolytic molecules on transduced T cells showing no difference between GFP⁺ and TRAIL⁺ T cells. (B, C) B6→CBF1+LB27.4 allo-BMT is described in Figure 1. (B) Necropsy was performed on animals found dead during survival monitoring and the cause of death tabulated. (C) Weekly GVHD clinical scores. (** p<0.001).

Suppl Figure 2. Recipients of BALB/c→BALB/c syn-BMT were adoptively transferred with 5x10⁶/recipient B6 allo-preT cells. Spleen and thymus were harvested on (A) Day 14 and (B) Day 28 and the number of preT-derived cells calculated. (C) Percentage frequency of preT-derived splenic CD4 and CD8 T cells at day 28 were determined.

Suppl Figure 3. (A, B) B6→CBF1 allo-BMT is described in Figure 1A, B, C, D. Weekly weight changes as an indicator of GVHD was monitored. (C). B6→CBF1 allo-BMT were left either untreated or adoptively transferred with donor GFP⁺ and TRAIL⁺ T cells, and subsequently inoculated with LCMV. Splenocytes from the inoculated recipients were harvested and cocultured with vero cells to determine PFU/mg (*p<0.05, **p<0.001).

Suppl Figure 4. PBMCs from CLL patients – CLL-1 and CLL-2 – were analyzed by flow cytometry. (A) DAPI⁺excluded live events are studied for expression of
CD19 and CD5, showing 56% and 60% putative CLL cells. (B) DAPI−excluded live events are studied for expression of DR4 and DR5.
**A**

**B**

<table>
<thead>
<tr>
<th></th>
<th>Tumor</th>
<th>GVHD</th>
<th>Alive</th>
</tr>
</thead>
<tbody>
<tr>
<td>B6 BMT</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>B6 BMT+LB27.4</td>
<td>10</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>+GFP+ T cells</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>+TRAIL+ T cells</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

Tumor dose: 2x10^5/rcpt. T cell dose: 0.5x10^6/rcpt

**C**

**suppl Figure 1**
B6 preT cells + BALB/c → BALB/c

Suppl Figure 2

A Day 14

B Day 28

C

% Frequency

CD4

CD8
suppl Figure 4